GLP-1赛道竞争白热化:进口主导,国产减重药能否撕开差异化缺口?

21世纪经济报道
03 Jun

21世纪经济报道记者闫硕北京报道  GLP-1类减重药物领域又传来重磅消息。  6月2日,翰森制药宣布与Regeneron Pharmaceuticals, Inc.订立许可协议,授予Regeneron开发、生产及商业化HS-20094的全球独占许可(不含中国内地、香港及澳门)。HS-20094是一款在研GLP-1/GIP双受体激动剂,已成功完成多项Ⅱ期临床试验,具有积极的疗效和安全性数据,目前...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10